Why the study?
Does thromboprophylaxis prevent VTE in outpatients with cancer receiving chemotherapy?
Does thromboprophylaxis prevent VTE in outpatients with cancer receiving chemotherapy?
Outpatient chemotherapy patients are at increased risk for VTE and bleeding, requiring careful risk-benefit assessment before initiating thromboprophylaxis.
Demands individualized risk assessment before thromboprophylaxis in cancer outpatients; leaves open net clinical benefit.
Those undergoing chemotherapy as outpatients are at increased risk for VTE and for major bleeding complications. Thromboprophylaxis may be considered for such patients after carefully assessing the risks and benefits of treatment.
No takes yet. Share an insight, caveat, or question.
Lyman et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: